中国生物制药旗下南京正大天晴NTQ1062完成Ⅲ期临床首例患者入组给药

参考文献：

[1] 中国乳腺癌PIK3CA检测专家共识. 中华病理学杂志. 2025;54(2):120-125.

[2] Andrikopoulou A, Chatzinikolaou S, Panourgias E, et al. The emerging role of capivasertib in breast cancer[J]. Breast, 2022, 63: 157-167. DOI: 10.1016/j. breast. 2022. 03.018.

[3] Jiang YZ, Ma D, Jin X, et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities[J]. Nat Cancer, 2024, 5(4):673-690. DOI:10.1038/s43018-024-00725-0.

[4] Deng L, Zhu XH, Sun Y, et al. Prevalence and prognostic role of PIK3CA/AKT1 mutations in chinese breast cancer patients[J]. Cancer Res Treat, 2019, 51(1): 128-140. DOI: 10.4143/crt.2017.598.

[5] DAVOODI-MOGHADDAM Z，JAFARI-RADDANI F，DELSHAD M，et al. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies： trend of current clinical trials[J]. J Cancer Res Clin Oncol，2023，149（16）：15293-15310.

[6] Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017 Apr 20;169(3):381-405.

[7]Howlader N, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106 (2014).

[8] Gerosa R, et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit Rev Oncol Hematol  196, 104324 (2024).

[9] Freeman-Cook K, et al. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. Cancer Cell  39, 1404-21. e11  (2021).

[10] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 5.2025)[S]. Plymouth: NCCN, 2025.

[11] 中国临床肿瘤学会乳腺癌专家委员会. 中国临床肿瘤学会（CSCO）乳腺癌诊疗指南（2025年版）[S]. 北京: 人民卫生出版社, 2025.